TR201906295T4 - IL-4 R alfaya bağlanan gözyaşı lipokalini muteinleri. - Google Patents
IL-4 R alfaya bağlanan gözyaşı lipokalini muteinleri. Download PDFInfo
- Publication number
- TR201906295T4 TR201906295T4 TR2019/06295T TR201906295T TR201906295T4 TR 201906295 T4 TR201906295 T4 TR 201906295T4 TR 2019/06295 T TR2019/06295 T TR 2019/06295T TR 201906295 T TR201906295 T TR 201906295T TR 201906295 T4 TR201906295 T4 TR 201906295T4
- Authority
- TR
- Turkey
- Prior art keywords
- mutein
- sequence
- amino acid
- muteins
- lipocalin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35246110P | 2010-06-08 | 2010-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201906295T4 true TR201906295T4 (tr) | 2019-05-21 |
Family
ID=44627297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/06295T TR201906295T4 (tr) | 2010-06-08 | 2011-06-08 | IL-4 R alfaya bağlanan gözyaşı lipokalini muteinleri. |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US8986951B2 (https=) |
| EP (1) | EP2580236B1 (https=) |
| JP (3) | JP5902679B2 (https=) |
| CN (3) | CN105949301B (https=) |
| AU (1) | AU2011263786B2 (https=) |
| CA (1) | CA2800026C (https=) |
| CY (1) | CY1122339T1 (https=) |
| DK (1) | DK2580236T3 (https=) |
| ES (1) | ES2729652T3 (https=) |
| HR (1) | HRP20190689T1 (https=) |
| HU (1) | HUE043835T2 (https=) |
| LT (1) | LT2580236T (https=) |
| NZ (1) | NZ603562A (https=) |
| PL (1) | PL2580236T3 (https=) |
| PT (1) | PT2580236T (https=) |
| RS (1) | RS58839B1 (https=) |
| RU (1) | RU2569745C2 (https=) |
| SG (1) | SG186161A1 (https=) |
| SI (1) | SI2580236T1 (https=) |
| SM (1) | SMT201900297T1 (https=) |
| TR (1) | TR201906295T4 (https=) |
| WO (1) | WO2011154420A2 (https=) |
| ZA (1) | ZA201209160B (https=) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9829494B2 (en) | 2005-12-01 | 2017-11-28 | Adrenomed Ag | Methods of treatment using ADM antibodies |
| PL2580236T3 (pl) | 2010-06-08 | 2019-09-30 | Pieris Pharmaceuticals Gmbh | Muteiny lipokaliny łez wiążące IL-4 R alfa |
| ES2494190T3 (es) | 2011-11-16 | 2014-09-15 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo |
| PT2780371T (pt) | 2011-11-16 | 2019-01-30 | Adrenomed Ag | Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica |
| LT3553084T (lt) | 2011-11-16 | 2023-03-10 | Adrenomed Ag | Anti-adrenomedulino (adm) antikūnas arba anti-adm antikūno fragmentas, arba anti-adm ne-ig karkasas, skirtas organų funkcijos sutrikimo arba organų nepakankamumo profilaktikai arba sumažinimui paciento, sergančio lėtine arba ūmine liga arba esančio ūminės būklės, organizme |
| EP2780370B1 (en) | 2011-11-16 | 2019-09-25 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| IL283215B2 (en) | 2011-11-16 | 2024-05-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment and pharmaceutical compostions comprising the same |
| HRP20170427T1 (hr) | 2011-11-16 | 2017-06-16 | Sphingotec Gmbh | Testovi na adrenomedulin i postupci određivanja zrelog adrenomedulina |
| EP3842058B1 (en) | 2011-12-13 | 2023-08-23 | Pieris Pharmaceuticals GmbH | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
| CN103308670B (zh) | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | 用于预测对象患糖尿病和/或代谢综合征的风险的方法 |
| CN103308689B (zh) | 2012-03-08 | 2017-04-12 | 思芬构技术有限公司 | 用于预测雌性对象中患上癌症的风险或诊断癌症的方法 |
| CN103308673B (zh) | 2012-03-08 | 2017-05-31 | 思芬构技术有限公司 | 用于预测雌性对象中发生心血管事件的风险的方法 |
| US9522940B2 (en) * | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| US9664695B2 (en) | 2012-10-02 | 2017-05-30 | Sphingotec Gmbh | Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction |
| US10526384B2 (en) * | 2012-11-19 | 2020-01-07 | Pieris Pharmaceuticals Gmbh | Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof |
| ES2879023T3 (es) | 2013-01-08 | 2021-11-19 | Sphingotec Gmbh | Niveles en ayunas de la hormona de crecimiento como marcador predictivo de riesgo cardiovascular |
| HK1213194A1 (zh) * | 2013-03-14 | 2016-06-30 | Daiichi Sankyo Co., Ltd. | 用於新型的结合蛋白质pcsk9 |
| SG11201507774YA (en) | 2013-03-20 | 2015-10-29 | Sphingotec Gmbh | Adrenomedullin to guide therapy of blood pressure decline |
| WO2015177175A2 (en) | 2014-05-22 | 2015-11-26 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| EP3002589A1 (en) | 2014-10-01 | 2016-04-06 | sphingotec GmbH | A method for stratifying a female subject for hormone replacement therapy |
| EP3245288A1 (en) * | 2015-01-12 | 2017-11-22 | Pieris Pharmaceuticals GmbH | Engineered t cells and uses therefor |
| CN107667294B (zh) | 2015-04-24 | 2021-12-17 | 思芬构技术有限公司 | 用于预测慢性肾病发生风险的方法 |
| MX2017014730A (es) | 2015-05-18 | 2018-06-28 | Pieris Pharmaceuticals Gmbh | Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3). |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| DE112017002105T5 (de) | 2016-04-21 | 2019-04-25 | Sphingotec Therapeutics Gmbh | Verfahren zur Bestimmung von DPP3 und therapeutische Verfahren |
| EP3474887A1 (en) | 2016-06-27 | 2019-05-01 | AiCuris Anti-infective Cures GmbH | Hcmv entry inhibitors |
| RU2019103403A (ru) | 2016-07-08 | 2020-08-10 | Сфинготек Гмбх | Адреномедуллин для оценки застоя у индивидуума с острой сердечной недостаточностью |
| EP3309550A1 (en) | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
| EP3339324A1 (en) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
| JP7727371B2 (ja) | 2016-12-16 | 2025-08-21 | アドレノメト アクチェンゲゼルシャフト | うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 |
| EP3631459A1 (en) | 2017-05-30 | 2020-04-08 | SphingoTec GmbH | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction |
| HRP20241795T1 (hr) | 2017-09-25 | 2025-03-14 | Adrenomed Ag | Anti-adrenomedulin (adm) – vezujući entitet za uporabu u terapiji ili prevenciji simptoma bolesti |
| WO2019077082A1 (en) | 2017-10-18 | 2019-04-25 | Adrenomed Ag | SURVEILLANCE OF THERAPY UNDER TREATMENT WITH ANTI-ADRENOMEDULIN BINDER (ADM) |
| JP7411546B2 (ja) | 2017-10-24 | 2024-01-11 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 初回心血管イベントの予測のためのセレノプロテインｐ |
| KR102835427B1 (ko) | 2017-10-25 | 2025-07-21 | 4틴4 파마슈티컬스 게엠베하 | 특이적 dpp3-에피토프에 대하여 지시되고 이에 결합하는 dpp3 결합제 및 산화적 스트레스와 연관되는 질환 / 급성 병태의 예방 또는 치료에서의 그의 용도 |
| CN119770645A (zh) | 2018-02-08 | 2025-04-08 | 斯弗因高泰克有限公司 | 用于诊断和/或预测痴呆症的肾上腺髓质素和抗肾上腺髓质素结合物在治疗或预防痴呆症中的应用 |
| EP3569614A1 (en) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase |
| EP3586865A1 (en) | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
| BR112021010069A2 (pt) | 2018-12-20 | 2021-11-23 | Sphingotec Gmbh | Selenoproteína p em insuficiência cardíaca |
| CN113557031A (zh) | 2018-12-21 | 2021-10-26 | 4Teen4制药有限公司 | 使用血管紧张肽受体激动剂和/或其前体的治疗的疗法指导和/或疗法监测 |
| US20220193191A1 (en) * | 2019-03-29 | 2022-06-23 | Astrazeneca Ab | Lipocalin mutein for treatment of asthma |
| EP3946417A1 (en) * | 2019-03-29 | 2022-02-09 | Pieris Pharmaceuticals GmbH | Inhaled administration of lipocalin muteins |
| AU2020328194A1 (en) | 2019-08-15 | 2022-03-17 | Sphingotec Gmbh | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients |
| JP2022546061A (ja) | 2019-08-30 | 2022-11-02 | ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ショック症治療のための治療法の誘導および／または治療法の監視 |
| US11231198B2 (en) | 2019-09-05 | 2022-01-25 | Trane International Inc. | Systems and methods for refrigerant leak detection in a climate control system |
| EP3871689A1 (en) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| CN115244080A (zh) | 2020-02-27 | 2022-10-25 | 艾德里诺医药公司 | 用于治疗或预防休克的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架 |
| US20230193348A1 (en) | 2020-02-27 | 2023-06-22 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock |
| US20230250166A1 (en) | 2020-02-27 | 2023-08-10 | Adrenomed Ag | Anti-adrenomedullin (adm) binder for use in therapy of patients in shock |
| AU2021238591A1 (en) | 2020-03-16 | 2022-11-17 | Adrenomed Ag | Pro-Adrenomedullin or fragment thereof in patients infected with Corona virus and treatments with binder against adrenomedullin |
| EP3922993A1 (en) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| BR112022017277A2 (pt) | 2020-03-16 | 2022-10-18 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 em pacientes infectados com coronavírus |
| EP4023218A1 (en) | 2020-12-02 | 2022-07-06 | S-Form Pharma | Combination therapy for patients having acute and/or persistent dyspnea |
| KR20230121785A (ko) | 2020-12-18 | 2023-08-21 | 아스트라제네카 에이비이 | 천식 치료용 리포칼린 뮤테인 건조 분말 제형 |
| CN117529664A (zh) | 2021-06-18 | 2024-02-06 | 思芬构技术有限公司 | 用于预测脓毒症和脓毒性休克的方法 |
| US20240310387A1 (en) | 2021-06-29 | 2024-09-19 | Berysol Gmbh | Composite biomarker for the identification of selenium deficiency in a bodily fluid |
| CN113943374B (zh) * | 2021-09-24 | 2024-04-30 | 广东菲鹏制药股份有限公司 | 一种白介素15及其受体的多肽复合物 |
| CA3254142A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | STABLE AQUEOUS FORMULATION OF AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADM ANTIBODY FRAGMENT |
| AU2023313376A1 (en) | 2022-07-29 | 2025-03-06 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| AU2023315168A1 (en) | 2022-07-29 | 2025-02-13 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
| JP2025541138A (ja) | 2022-12-15 | 2025-12-18 | ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 重篤な患者における肺機能の改善のためのｄｐｐ３阻害剤 |
| JP2026510789A (ja) | 2023-03-17 | 2026-04-10 | ペーアーエム セラノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | ペプチジルグリシンα－アミド化モノオキシゲナーゼ（ＰＡＭ）の測定法及び診断目的のためのその使用 |
| EP4687942A1 (en) | 2023-03-29 | 2026-02-11 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline |
| CN121889677A (zh) | 2023-09-25 | 2026-04-17 | 思芬构技术有限公司 | 用于肾移植患者中移植物功能降低的早期诊断、早期预测、监测或严重程度预测的方法 |
| WO2025229075A1 (en) | 2024-05-03 | 2025-11-06 | Sphingotec Gmbh | A method for the specific determination of proenkephalin fragment 119-159 |
| WO2025248139A1 (en) | 2024-05-31 | 2025-12-04 | 4TEEN4 Pharmaceuticals GmbH | Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof |
| EP4675277A1 (en) | 2024-07-05 | 2026-01-07 | Predemtec AG | A method for diagnosing alzheimer´s disease or determining the risk of suffering from alzheimer´s disease |
| WO2026046978A1 (en) | 2024-08-26 | 2026-03-05 | Pam Theragnostics Gmbh | Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects |
| WO2026046968A1 (en) | 2024-08-26 | 2026-03-05 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 binders for the treatment of endothelial dysfunction |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| US6446467B1 (en) | 1997-07-29 | 2002-09-10 | Physical Optics Corporation | Monolithic glass light shaping diffuser and method for its production |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| DK1087778T3 (da) | 1998-06-08 | 2005-12-19 | Hoffmann La Roche | Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| US6399857B1 (en) * | 1999-09-22 | 2002-06-04 | Paradigm Genetics, Inc. | Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species |
| AU2002335930B2 (en) | 2001-03-09 | 2005-07-28 | Morphosys Ag | Serum albumin binding moieties |
| WO2003029471A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| AU2003233583A1 (en) | 2002-05-24 | 2003-12-12 | Agennix Incorporated | Oral lactoferrin in the treatment of respiratory disorders |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| AU2003264100A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
| RU2389796C2 (ru) * | 2003-08-29 | 2010-05-20 | Аэровэнс, Инк. | Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид |
| US7404957B2 (en) | 2003-08-29 | 2008-07-29 | Aerovance, Inc. | Modified IL-4 mutein receptor antagonists |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| JP2009509535A (ja) | 2005-09-27 | 2009-03-12 | アムニクス， インコーポレイテッド | タンパク様薬剤およびその使用 |
| US8598317B2 (en) | 2006-03-20 | 2013-12-03 | Technische Universitaet Muenchen | Muteins of tear lipocalin with affinity for the T-cell coreceptor CD4 |
| ES2354653T3 (es) * | 2006-08-01 | 2011-03-16 | Pieris Ag | Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas. |
| EP2046820B1 (en) * | 2006-08-01 | 2010-10-20 | Pieris AG | Muteins of tear lipocalin and methods for obtaining the same |
| KR20100047866A (ko) | 2007-07-11 | 2010-05-10 | 애로반스, 인코포레이티드 | 약제학적 폴리펩타이드 건조 분말 에어로졸 제형 및 이의 제조 방법 |
| PL2580236T3 (pl) * | 2010-06-08 | 2019-09-30 | Pieris Pharmaceuticals Gmbh | Muteiny lipokaliny łez wiążące IL-4 R alfa |
| EP3842058B1 (en) * | 2011-12-13 | 2023-08-23 | Pieris Pharmaceuticals GmbH | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
-
2011
- 2011-06-08 PL PL11726380T patent/PL2580236T3/pl unknown
- 2011-06-08 SM SM20190297T patent/SMT201900297T1/it unknown
- 2011-06-08 HU HUE11726380A patent/HUE043835T2/hu unknown
- 2011-06-08 TR TR2019/06295T patent/TR201906295T4/tr unknown
- 2011-06-08 RU RU2012150766/15A patent/RU2569745C2/ru active
- 2011-06-08 JP JP2013513670A patent/JP5902679B2/ja not_active Expired - Fee Related
- 2011-06-08 CN CN201610143597.4A patent/CN105949301B/zh not_active Expired - Fee Related
- 2011-06-08 DK DK11726380.6T patent/DK2580236T3/da active
- 2011-06-08 NZ NZ603562A patent/NZ603562A/en not_active IP Right Cessation
- 2011-06-08 EP EP11726380.6A patent/EP2580236B1/en active Active
- 2011-06-08 RS RS20190510A patent/RS58839B1/sr unknown
- 2011-06-08 AU AU2011263786A patent/AU2011263786B2/en not_active Ceased
- 2011-06-08 LT LTEP11726380.6T patent/LT2580236T/lt unknown
- 2011-06-08 HR HRP20190689TT patent/HRP20190689T1/hr unknown
- 2011-06-08 US US13/702,792 patent/US8986951B2/en active Active
- 2011-06-08 SI SI201131711T patent/SI2580236T1/sl unknown
- 2011-06-08 ES ES11726380T patent/ES2729652T3/es active Active
- 2011-06-08 CN CN202010135181.4A patent/CN111499725A/zh active Pending
- 2011-06-08 CA CA2800026A patent/CA2800026C/en active Active
- 2011-06-08 PT PT11726380T patent/PT2580236T/pt unknown
- 2011-06-08 WO PCT/EP2011/059420 patent/WO2011154420A2/en not_active Ceased
- 2011-06-08 SG SG2012089116A patent/SG186161A1/en unknown
- 2011-06-08 CN CN201180028367.9A patent/CN103038249B/zh not_active Expired - Fee Related
-
2012
- 2012-12-05 ZA ZA2012/09160A patent/ZA201209160B/en unknown
-
2015
- 2015-03-23 US US14/665,692 patent/US9687524B2/en not_active Expired - Fee Related
- 2015-11-06 JP JP2015218174A patent/JP2016028604A/ja active Pending
-
2017
- 2017-06-05 US US15/613,958 patent/US10232014B2/en active Active
-
2019
- 2019-01-24 US US16/256,331 patent/US10898545B2/en not_active Expired - Fee Related
- 2019-01-30 JP JP2019014631A patent/JP6766194B2/ja not_active Expired - Fee Related
- 2019-06-06 CY CY20191100604T patent/CY1122339T1/el unknown
-
2020
- 2020-12-16 US US17/124,141 patent/US20210196788A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10898545B2 (en) | Tear lipocalin muteins binding IL-4 r alpha | |
| JP5562257B2 (ja) | ヒトｃ−ｍｅｔ受容体のチロシンキナーゼに対し親和性を有する涙液リポカリンの変異タンパク質、及びそれを得るための方法 | |
| RU2756318C2 (ru) | Мутеины липокалина 2 человека с аффинностью в отношении глипикана-3 (gpc3) | |
| WO2009149339A2 (en) | P53 activator peptides | |
| CN105246503A (zh) | Pcsk9的新颖结合蛋白 | |
| RU2802488C1 (ru) | Белковая конструкция на основе рецептор-специфичного мутантного варианта противоопухолевого цитокина TRAIL в виде гибридного белка с пептидом, специфичным к интегрину αvβ3, для терапии солидных опухолей | |
| HK1232549B (zh) | 结合IL-4受体α的泪脂质运载蛋白突变蛋白 | |
| HK1232549A1 (en) | Tear lipocalin muteins binding il-4 r alpha | |
| EA049562B1 (ru) | Гибридная белковая конструкция на основе рецептор-специфичного варианта trail с пептидом, специфичным к интегрину альфа v бета 3, для терапии солидных опухолей | |
| WO2024019642A1 (ru) | ГИБРИДНАЯ БЕЛКОВАЯ КОНСТРУКЦИЯ НА ОСНОВЕ РЕЦЕПТОР-СПЕЦИФИЧНОГО ВАРИАНТА TRAIL С ПЕПТИДОМ, СПЕЦИФИЧНЫМ К αVβ3-ИНТЕГРИНУ | |
| TW201524994A (zh) | Ｐｃｓｋ９新穎結合蛋白 |